To describe the treatment perception from patients with non-valvular atrial fibrillation (NVAF) receiving Pradaxa® or VKA for stroke prevention by using the self-estimation questionnaire of PACT-Q during a 6-month study period.
- Pradaxa® Drug
Other Names: Dabigatran etexilate Intervention Desc: Dabigatran etexilate ARM 1: Kind: Experimental Label: Cohort A Description: consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa® ARM 2: Kind: Experimental Label: Cohort B Description: patients being newly diagnosed with NVAF and initiated on Pradaxa®
Patients 20 years of age or older with a diagnosis of non-valvular atrial fibrillation (NVAF).
|Type||Measure||Time Frame||Safety Issue|
|Primary||Mean PACT-Q2 scores compared to baseline||30-45 days and 150-210 days|
|Primary||Mean PACT-Q2 scores compared between 2 treatment groups.||30-45 days and 150-210 days|
|Secondary||Mean PACT-Q2 score at the last assessment (150-210 days) compared to the second assessment (30-45 days)||30-45 days and 150-210 days|
|Secondary||Description of mean PACT-Q1 score at baseline||day 1|
- Boehringer Ingelheim Lead